292 related articles for article (PubMed ID: 11087333)
41. Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft.
Karacay H; Brard PY; Sharkey RM; Chang CH; Rossi EA; McBride WJ; Ragland DR; Horak ID; Goldenberg DM
Clin Cancer Res; 2005 Nov; 11(21):7879-85. PubMed ID: 16278412
[TBL] [Abstract][Full Text] [Related]
42. Imaging doxorubicin and polymer-drug conjugates of doxorubicin-induced cardiotoxicity with bispecific anti-myosin-anti-DTPA antibody and Tc-99m-labeled polymers.
Panwar R; Bhattarai P; Patil V; Gada K; Majewski S; Khaw BA
J Nucl Cardiol; 2019 Aug; 26(4):1327-1344. PubMed ID: 29392624
[TBL] [Abstract][Full Text] [Related]
43. Comparative targeting of human colon-carcinoma multicell spheroids using one- and two-step (bispecific antibody) techniques.
Devys A; Thedrez P; Gautherot E; Faivre-Chauvet A; Saï-Maurel C; Rouvier E; Auget JL; Barbet J; Chatal JF
Int J Cancer; 1996 Sep; 67(6):883-91. PubMed ID: 8824563
[TBL] [Abstract][Full Text] [Related]
44. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody.
Sharkey RM; Cardillo TM; Rossi EA; Chang CH; Karacay H; McBride WJ; Hansen HJ; Horak ID; Goldenberg DM
Nat Med; 2005 Nov; 11(11):1250-5. PubMed ID: 16258537
[TBL] [Abstract][Full Text] [Related]
45. MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with
Ku A; Chan C; Aghevlian S; Cai Z; Cescon D; Bratman SV; Ailles L; Hedley DW; Reilly RM
Mol Pharm; 2019 Aug; 16(8):3559-3568. PubMed ID: 31242384
[TBL] [Abstract][Full Text] [Related]
46. Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells.
Rossi EA; Chang CH; Losman MJ; Sharkey RM; Karacay H; McBride W; Cardillo TM; Hansen HJ; Qu Z; Horak ID; Goldenberg DM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7122s-7129s. PubMed ID: 16203811
[TBL] [Abstract][Full Text] [Related]
47. Immunohistology of carcinoembryonic antigen (CEA)-expressing tumors grafted in nude mice after radioimmunotherapy with 131I-labeled bivalent hapten and anti-CEA x antihapten bispecific antibody.
Gautherot E; Kraeber-Bodéré F; Daniel L; Fiche M; Rouvier E; Saï-Maurel C; Thedrez P; Chatal JF; Barbet J
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3177s-3182s. PubMed ID: 10541361
[TBL] [Abstract][Full Text] [Related]
48. A divalent hapten-peptide induces apoptosis in human non hodgkin lymphoma cell lines targeted by anti-CD20xanti-hapten bispecific antibodies.
Brard PY; Karacay H; Stein R; Sharkey RM; Mattes MJ; Chang CH; Rossi EA; McBride WJ; Goldenberg DM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5564s-5571s. PubMed ID: 17875790
[TBL] [Abstract][Full Text] [Related]
49. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
van Schaijk FG; Oosterwijk E; Molkenboer-Kuenen JD; Soede AC; McBride BJ; Goldenberg DM; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2005 Mar; 46(3):495-501. PubMed ID: 15750164
[TBL] [Abstract][Full Text] [Related]
50. Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody.
Mirallié E; Saï-Maurel C; Faivre-Chauvet A; Regenet N; Chang CH; Goldenberg DM; Chatal JF; Barbet J; Thedrez P
Eur J Nucl Med Mol Imaging; 2005 Aug; 32(8):901-9. PubMed ID: 15864584
[TBL] [Abstract][Full Text] [Related]
51. Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten.
Gautherot E; Bouhou J; Le Doussal JM; Manetti C; Martin M; Rouvier E; Barbet J
Cancer; 1997 Dec; 80(12 Suppl):2618-23. PubMed ID: 9406716
[TBL] [Abstract][Full Text] [Related]
52. Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.
Sharkey RM; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
Semin Nucl Med; 2010 May; 40(3):190-203. PubMed ID: 20350628
[TBL] [Abstract][Full Text] [Related]
53. Improvement of the Targeting of Radiolabeled and Functionalized Liposomes with a Two-Step System Using a Bispecific Monoclonal Antibody (Anti-CEA × Anti-DTPA-In).
Rauscher A; Frindel M; Rajerison H; Gouard S; Maurel C; Barbet J; Faivre-Chauvet A; Mougin-Degraef M
Front Med (Lausanne); 2015; 2():83. PubMed ID: 26636087
[TBL] [Abstract][Full Text] [Related]
54. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
55. Clinical-scale radiolabeling of a humanized anticarcinoembryonic antigen monoclonal antibody, hMN-14, with residualizing 131I for use in radioimmunotherapy.
Govindan SV; Griffiths GL; Stein R; Andrews P; Sharkey RM; Hansen HJ; Horak ID; Goldenberg DM
J Nucl Med; 2005 Jan; 46(1):153-9. PubMed ID: 15632046
[TBL] [Abstract][Full Text] [Related]
56. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.
Barbet J; Peltier P; Bardet S; Vuillez JP; Bachelot I; Denet S; Olivier P; Leccia F; Corcuff B; Huglo D; Proye C; Rouvier E; Meyer P; Chatal JF
J Nucl Med; 1998 Jul; 39(7):1172-8. PubMed ID: 9669389
[TBL] [Abstract][Full Text] [Related]
57. In vitro and in vivo comparison of binding of 99m-Tc-labeled anti-CEA MAb F33-104 with 99m-Tc-labeled anti-CEA MAb BW431/26.
Watanabe N; Oriuchi N; Sugiyama S; Kuroki M; Matsuoka Y; Tanada S; Murata H; Inoue T; Sasaki Y
Nuklearmedizin; 1999; 38(4):115-9. PubMed ID: 10392376
[TBL] [Abstract][Full Text] [Related]
58. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten.
Gautherot E; Rouvier E; Daniel L; Loucif E; Bouhou J; Manetti C; Martin M; Le Doussal JM; Barbet J
J Nucl Med; 2000 Mar; 41(3):480-7. PubMed ID: 10716323
[TBL] [Abstract][Full Text] [Related]
59. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model.
Sharkey RM; Karacay H; Griffiths GL; Behr TM; Blumenthal RD; Mattes MJ; Hansen HJ; Goldenberg DM
Bioconjug Chem; 1997; 8(4):595-604. PubMed ID: 9258460
[TBL] [Abstract][Full Text] [Related]
60. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections.
Kraeber-Bodéré F; Faivre-Chauvet A; Saï-Maurel C; Campion L; Fiche M; Gautherot E; Le Boterff J; Barbet J; Chatal JF; Thédrez P
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3183s-3189s. PubMed ID: 10541362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]